Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: The impact of 2-18F-fluoro-2-deoxy-d-glucose positron emission tomogram mediastinal staging

European Journal of Cardio-thoracic Surgery

Volumn 39, Issue 1, 2011, Pages 96-101

  Barnett, Stephen ^a   Baste, Jean Marc ^b   Murugappan, Kowsi ^a   Tog, Check ^a   Berlangieri, Salvatore ^a   Scott, Andrew ^a   Seevanayagam, Siven ^a   Knight, Simon ^a  

^a AUSTIN HEALTH   (Australia)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Lymph node staging; Non small cell lung cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MEDIASTINUM CANCER; MEDIASTINUM LYMPH NODE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL TIME; THORACOTOMY; UNIVARIATE ANALYSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; EPIDEMIOLOGIC METHODS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 78651100874     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.04.040     Document Type: Article

References (25)

1. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
2. Detterbeck F. What to do with "Surprise" N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 2008, 3:289-302.
3. de Geus-Oei L.F., van der Heijden H.F., Corstens F.H., Oyen W.J. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007, 110:1654-1664.
4. Downey R.J., Akhurst T., Gonen M., Park B., Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2007, 133:1419-1427.
5. Mountain C.F., Dresler C.M. Regional lymph node classification for lung cancer staging. Chest 1997, 111:1718-1723.
6. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., Grodzki T., Pereira J.R., Le Groumellec A., Lorusso V., Clary C., Torres A.J., Dahabreh J., Souquet P.J., Astudillo J., Fournel P., Artal-Cortes A., Jassem J., Koubkova L., His P., Riggi M., Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
7. Roth J.A., Atkinson E.N., Fossella F., Komaki R., Bernadette Ryan M., Putnam J.B., Lee J.S., Dhingra H., De Caro L., Chasen M., Hong W.K. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998, 21:1-6.
8. Rosell R., Gomez-Codina J., Camps C., Javier Sanchez J., Maestre J., Padilla J., Canto A., Abad A., Roig J. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999, 26:7-14.
9. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., Tjan-Heijnen V.C., Biesma B., Debruyne C., van Zandwijk N., Splinter T.A., Giaccone G. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007, 99:442-450.
10. Albain K.S., Swann R.S., Rusch V.W., Turrisi A.T., Shepherd F.A., Smith C., Chen Y., Livingston R.B., Feins R.H., Gandara D.R., Fry W.A., Darling G., Johnson D.H., Green M.R., Miller R.C., Ley J., Sause W.T., Cox J.D. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374:379-386.
11. Thomas M., Rube C., Hoffknecht P., Macha H.N., Freitag L., Linder A., Willich N., Hamm M., Sybrecht G.W., Ukena D., Deppermann K.M., Droge C., Riesenbeck D., Heinecke A., Sauerland C., Junker K., Berdel W.E., Semik M. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008, 9:636-648.
12. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., Demedts M.G. Survival and prognosis factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997, 63:1441-1450.
13. Burdett S.S., Stewart L.A., Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev 2007, CD006157.
14. Na I.I., Cheon G.J., Choe D.H., Byun B.H., Kang H.J., Koh J.S., Park J.H., Baek H., Ryoo B.Y., Lee J.C., Yang S.H. Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective study. Lung Cancer 2008, 60:69-74.
15. Okereke I.C., Gangadharan S.P., Kent M.S., Nicotera S.P., Shen C., DeCamp M.M. Standard uptake value predicts survival in non-small cell lung cancer. Ann Thorac Surg 2009, 88:911-915. discussion 915-6.
16. Sasaki R., Komaki R., Macapinlac H., Erasmus J., Allen P., Forster K., Putnam J.B., Herbst R.S., Moran C.A., Podoloff D.A., Roth J.A., Cox J.D. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005, 23:1136-1143.
17. Nagai K., Tsuchiya R., Mori T., Tada H., Ichinose Y., Koike T., Kato H. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003, 125:254-260.
18. Pass H.I., Pogrebniak H.W., Steinberg S.M., Mulshine J., Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992, 53:992-998.
19. Johnstone D.W., Byhardt R.W., Ettinger D., Scott C.B. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002, 54:365-369.
20. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215.
21. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., Movsas B., Wasserman T., Sause W., Cox J.D. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003, 621a. [abstr 2499].
22. Berlangieri S.U., Scott A.M., Knight S.R., Fitt G.J., Hennessy O.F., Tochon-Danguy H.J., Clarke C.P., McKay W.J. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 1999, 16(Suppl. 1):S25-S30.
23. Gould M.K., Kuschner W.G., Rydzak C.E., Maclean C.C., Demas A.N., Shigemitsu H., Chan J.K., Owens D.K. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003, 139:879-892.
24. Reed C.E., Harpole D.H., Posther K.E., Woolson S.L., Downey R.J., Meyers B.F., Heelan R.T., MacApinlac H.A., Jung S.H., Silvestri G.A., Siegel B.A., Rusch V.W. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003, 126:1943-1951.
25. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004, 45:1431-1434.